Skip to Main Content

Paper Details

Mutations in <i>BRCA1</i> and <i>BRCA2</i> differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
Nat Cancer
107
2021
BRCA1, BRCA1 and BRCA2-deficiency, BRCA2, BRCA2-deficient tumors, ICB, Single, T, T cell, advanced cancer, dendritic cell populations, homologous recombination genes, human, macrophage, mouse, natural killer, patients, tumor, tumors
Author NameAffiliation
Xin PeiMemorial Sloan Kettering Cancer Center
Vladimir MakarovMemorial Sloan Kettering Cancer Center
Vladimir MakarovMemorial Sloan Kettering Cancer Center
Fengshen KuoMemorial Sloan Kettering Cancer Center
Britta WeigeltMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
Elisa de StanchinaMemorial Sloan Kettering Cancer Center
Simon N PowellMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Nadeem RiazMemorial Sloan Kettering Cancer Center
Nadeem RiazMemorial Sloan Kettering Cancer Center
Nadeem RiazMemorial Sloan Kettering Cancer Center
  • 1 - 22

Datasets

Release 1.2